The rationale for a potentially favorable toxicity profile of OTUD6B directed therapies stems from LIN28B, the substrate of OTUD6B, which is typically only expressed in embryonic cells or in certain malignancies such as MM (Shyh‐Chang & Daley, 2013; Balzeau et al, 2017; Manier et al, 2017). This evidence concerns the gene OTUD6B and Miyoshi myopathy.